The objective of this project is to develop a novel extended wear contact lens with controllable and sustained release of latanoprost for the duration of wear to treat glaucoma. Glaucoma is the second leading cause of blindness in the world with the total number of cases estimated at over 70 million worldwide. There is a substantial need for more efficacious and convenient delivery of ocular therapeutics, especially glaucoma medication, via non-invasive platforms. Current treatment options predominantly consist of topical eye drops, which lead to significant peaks and valleys in drug concentration and intraocular pressure (IOP). The proposed work aims to solve these problems as well as poor patient compliance with increased latanoprost bioavailability and decreased side effects leading to significantly better patient outcomes. Novel, silicone hydrogel lenses will be rationally designed and synthesized with significant control over latanoprost release and loading while maintaining conventional lens properties such as optical clarity, mechanical properties, and oxygen diffusivity. The structure of the lens will be engineered by varying composition and polymerization conditions to produce macromolecular memory for latanoprost via non-covalent interactions within the polymer lens, leading to strict control of delivery rate and loading. Polymer lens structural, mechanical, optica properties will be characterized as well as in vitro latanoprost release at physiological flow conditions that match tear flow rate and turnover in the eye. In vivo latanoprost release from engineered contact lenses will be evaluated and compared to topical administration in canines measuring IOP and ocular concentration versus time. It is expected that engineered lenses will lead to a constant rate of latanoprost release and lead to approximately constant concentrations of drug in the eye, with little to no peaks and valleys, and a constant decreased IOP for the duration of lens wear.

Public Health Relevance

The objective of this project is to develop and test a new extended wear contact lens with extended time release of glaucoma medication. The lenses can replace the need for multiple eye drops for more efficient and effective treatment leading to significantly better patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21EY023094-01A1
Application #
8638312
Study Section
Biomaterials and Biointerfaces Study Section (BMBI)
Program Officer
Chin, Hemin R
Project Start
2014-03-01
Project End
2016-02-29
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$152,000
Indirect Cost
$49,297
Name
Auburn University at Auburn
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
066470972
City
Auburn University
State
AL
Country
United States
Zip Code
36849